"Growing Preference for Multimodal Treatment Approaches"
- The market is witnessing a shift toward combination therapies involving medication and therapeutic interventions like occupational and speech therapy.
- Pharmaceutical companies are investing in pediatric-specific drug formulations that support neuroplasticity during early childhood development.
- Care models are evolving to include cognitive training, behavioral therapy, and pharmacotherapy for more comprehensive patient management.
- For instance, in 2024, new extended-release formulations of nootropics and attention-enhancing drugs showed promising results in improving task execution time and fine motor function in children with dyspraxia.
- The integration of pharmaceutical innovation with therapeutic disciplines is reshaping the treatment landscape, offering synergistic benefits and improving functional outcomes
